Login to Your Account

Pharma: Other News To Note

Wednesday, November 21, 2012
• Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the European Commission approved Eliquis (apixaban) for prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation with one or more risk factors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription